DrugPatentWatch Database Preview
Deciphera Pharms Company Profile
Email this page to a colleague
What is the competitive landscape for DECIPHERA PHARMS, and when can generic versions of DECIPHERA PHARMS drugs launch?
DECIPHERA PHARMS has one approved drug.
There are three US patents protecting DECIPHERA PHARMS drugs.
There are twenty-seven patent family members on DECIPHERA PHARMS drugs in ten countries.
Summary for Deciphera Pharms
| International Patents: | 27 |
| US Patents: | 3 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Deciphera Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | 8,188,113 | Get Started Free | Y | Y | Get Started Free | ||
| Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | 8,461,179 | Get Started Free | Y | Y | Get Started Free | ||
| Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | Get Started Free | Get Started Free | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Deciphera Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 101110530 | Get Started Free |
| Eurasian Patent Organization | 026730 | Get Started Free |
| Eurasian Patent Organization | 200970279 | Get Started Free |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
